Oculis Holding AG (OCS) Cash from Operations (2022 - 2026)
Oculis Holding AG (OCS) posted quarterly Cash from Operations of 19585420.81 for Q1 2026, up 7.14% year-over-year from 18280015.07 in Q1 2025, and up 6.16% quarter-over-quarter from 20870763.3 in Q4 2025.
Oculis Holding AG (OCS) Cash from Operations (2022 - 2026) Analysis & Trends
Oculis Holding AG's Cash from Operations history runs 5 years deep, the most recent figure standing at 19585420.81 for Q1 2026.
- In Q1 2026, Cash from Operations rose 7.14% year-over-year to 19585420.81; the TTM figure through Mar 2026 stood at 78056596.89 (down 28.13% YoY), while the FY2025 annual figure was 79971143.7, down 43.82% from the prior year.
- Cash from Operations for Q1 2026 stood at 19585420.81, up from 20870763.3 in the prior quarter.
- The five-year high for Cash from Operations was 6781397.15 in Q4 2022, with the low at 21091606.91 in Q1 2025.
- The 5-year median for Cash from Operations is 15718761.35 (2024), against an average of 15322007.63.
- The sharpest annual moves came in 2023 and 2024: Cash from Operations plunged 136.21% in 2023, then gained 24.15% in 2024.
- Oculis Holding AG's Cash from Operations stood at 6781397.15 in 2022, then slumped by 136.21% to 16018579.72 in 2023, then gained by 24.15% to 12150358.55 in 2024, then sank by 71.77% to 20870763.3 in 2025, then grew by 6.16% to 19585420.81 in 2026.
- Business Quant data shows OCS's Cash from Operations at 19585420.81 in Q1 2026, 20870763.3 in Q4 2025, and 16773969.47 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Oculis Holding AG | 879.09 Mn | 590.21 Mn | - | -25.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -25.60 Mn |
| Jun 30, 2026 | -25.60 Mn |
| Mar 31, 2026 | -19.59 Mn |
| Mar 31, 2026 | -19.59 Mn |
| Dec 31, 2025 | -20.87 Mn |
| Dec 31, 2025 | -20.87 Mn |
| Sep 30, 2025 | -16.77 Mn |
| Sep 30, 2025 | -16.77 Mn |
| Jun 30, 2025 | -20.83 Mn |
| Jun 30, 2025 | -20.83 Mn |
| Mar 31, 2025 | -21.09 Mn |
| Mar 31, 2025 | -21.09 Mn |
| Dec 31, 2024 | -12.15 Mn |
| Dec 31, 2024 | -12.15 Mn |
| Sep 30, 2024 | -12.48 Mn |
| Sep 30, 2024 | -12.48 Mn |
| Jun 30, 2024 | -15.19 Mn |
| Jun 30, 2024 | -15.19 Mn |
| Mar 31, 2024 | -15.72 Mn |
| Mar 31, 2024 | -15.72 Mn |